Literature DB >> 14713776

Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm.

S Machele Donat1, Amanda North, Guido Dalbagni, Harry W Herr.   

Abstract

PURPOSE: Recurrent superficial papillary bladder tumors are most commonly treated with transurethral resection with the patient under anesthesia. We report our experience with office fulguration of small, recurrent, low grade papillary tumors using flexible cystodiathermy.
MATERIALS AND METHODS: We conducted a prospective single institution analysis of 267 consecutive patients with superficial bladder cancer undergoing routine bladder cancer surveillance between January 1998 and December 2001. Cytological and histological recurrences were recorded. Selection criteria for office fulguration were less than 5 low grade appearing papillary tumors, tumor size less than 0.5 cm, negative urine cytology and patient desire. All patients completed initial treatment (transurethral resection, partial cystectomy and/or intravesical therapy) and a minimum of 6 months on surveillance without recurrence (median 11.57 months).
RESULTS: Flexible cystodiathermy for small, low grade, recurrent papillary tumors was efficacious and well tolerated. Of the 123 patients 46% experienced 1 or more tumor recurrences (range 1 to 11) in a median followup of 2.6 years. Of these 123, 74 (60%) underwent office cystodiathermy. No difference was seen in disease specific survival (p = 0.1633) or disease progression (p = 0.860). When stratified by risk of recurrence 202 of 267 patients at high risk (76%) with low grade papillary recurrence had similar rates of progression to patients at low risk (p = 0.9025). Median time from diagnosis was 6.84 years, and time from last tumor was 20.4 months.
CONCLUSIONS: Office cystodiathermy of small, low grade papillary recurrence is safe and efficacious in properly selected patients. This change in practice can potentially improve patient quality of life and have a major economic impact on health care.

Entities:  

Mesh:

Year:  2004        PMID: 14713776     DOI: 10.1097/01.ju.0000103100.22951.5e

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients.

Authors:  Muhammet Fatih Kılınç; Göksel Bayar; Ayhan Dalkılıç; Nurettin Cem Sönmez; Serdar Arısan; Soner Güney
Journal:  Turk J Urol       Date:  2017-01-06

2.  Audit of safety, efficacy, and cost-effectiveness of local anaesthetic cystodiathermy.

Authors:  Kim Davenport; Francis X Keeley; Anthony G Timoney
Journal:  Ann R Coll Surg Engl       Date:  2010-07-02       Impact factor: 1.891

3.  External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer.

Authors:  Virginia Hernández; E De La Peña; M D Martin; C Blázquez; F J Diaz; C Llorente
Journal:  World J Urol       Date:  2010-12-29       Impact factor: 4.226

4.  A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients.

Authors:  Toru Yamada; Kunihiro Tsuchiya; Seiichi Kato; Shingo Kamei; Mitsuhiro Taniguchi; Toshimi Takeuchi; Naoki Yamamoto; Hidetoshi Ehara; Takashi Deguchi
Journal:  Int J Clin Oncol       Date:  2010-03-02       Impact factor: 3.402

5.  Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.

Authors:  Cosimo De Nunzio; Antonio Carbone; Simone Albisinni; Giorgio Alpi; Andrea Cantiani; Marcello Liberti; Andrea Tubaro; Francesco Iori
Journal:  World J Urol       Date:  2011-05-19       Impact factor: 4.226

6.  Micro-cost analysis of single-use vs. reusable cystoscopy in a single-payer healthcare system.

Authors:  Jaehoon Kim; Bruce Gao; Naeem Bhojani; Kevin C Zorn; Bilal Chughtai; Dean S Elterman
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

7.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

8.  Vertebral Osteomyelitis Secondary to Bacillus Calmette-Guérin Instillation Therapy for Transitional Cell Carcinoma In Situ.

Authors:  Tariq M Jaber; Mohammad Samiullah; Amy Surti
Journal:  Cureus       Date:  2021-04-20

9.  The value of extended good quality transurethral resection of bladder tumour in the treatment of the newly diagnosed bladder cancer.

Authors:  Mohamed Adel Atta; Ahmed Fouad Kotb; Mohamed Sharafeldeen; Ahmed Elabbady; Mohamed Mohie Hashad
Journal:  Arab J Urol       Date:  2016-11-26

10.  The Influence of Inverted Growth Pattern on Recurrence for Patients with Non-Invasive Low Grade Papillary Urothelial Carcinoma of Bladder.

Authors:  Sehbal Arslankoz; İbrahim Kulaç; Dilek Ertoy Baydar
Journal:  Balkan Med J       Date:  2017-04-13       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.